The pharmaceutical industry is the least trusted by the public — and it’s not hard to see why. The rise of OxyContin and the ensuing opioid crisis is one of the greatest preventable tragedies of our times, touching almost everyone.
But if we failed to prevent bad incentives from reigning supreme in the marketing of OxyContin, how can we stop something similar from happening next time?
In this episode, Dr. William Soliman, Founder and CEO of Accreditation Council for Medical Affairs (ACMA), takes a hard look at the issue — how we got here and how to prevent it from happening again.
We discuss:
- The marketing malfeasance that fueled the opioid epidemic
- Accreditation programs to curb these bad incentives
- What the future holds for the pharmaceutical industry
